Zhu Weiyou, Røe Oluf Dimitri, Wu Chen, Li Wei, Guo Renhua, Gu Yanhong, Liu Yiqian, Shu Yongqian, Chen Xiaofeng
J Chemother. 2015 Aug;27(4):221-6. doi: 10.1179/1973947815Y.0000000005. Epub 2015 Mar 3.
This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). A total of 30 patients with adenocarcinoma were included. Nine patients had solitary, and 21 patients had multiple BM. At evaluation after two cycles, the complete response (CR) rate, partial response (PR) rate, and stable disease (SD) for brain lesions was 0, 33.3, and 46.7%, respectively. The overall CR, PR, and SD were 0, 23.3, and 46.7%, respectively. The median time to tumour progression of BM (TTP-BM) was 6.0 months (95% CI 4.068-7.932). The median progression-free survival (PFS) and overall survival (OS) were 5.0 months (95% CI 4.197-5.803) and 11.0 months (95% CI 7.398-14.602), respectively. Pemetrexed has comparable activity on brain lesions as on extracranial tumours in advanced lung adenocarcinoma patients with inoperable and asymptomatic BM.
本回顾性研究旨在评估培美曲塞与顺铂/卡铂联合作为一线治疗方案，用于不可手术切除且无症状的非小细胞肺癌（NSCLC）脑转移（BM）的疗效。共纳入30例腺癌患者。其中9例为单发脑转移，21例为多发脑转移。两个周期治疗后的评估结果显示，脑病灶的完全缓解（CR）率、部分缓解（PR）率和疾病稳定（SD）率分别为0、33.3%和46.7%。总体CR、PR和SD率分别为0、23.3%和46.7%。脑转移瘤（TTP-BM）的中位肿瘤进展时间为6.0个月（95%CI 4.068-7.932）。中位无进展生存期（PFS）和总生存期（OS）分别为5.0个月（95%CI 4.197-5.803）和11.0个月（95%CI 7.398-14.602）。在不可手术切除且无症状脑转移的晚期肺腺癌患者中，培美曲塞对脑病灶的活性与对颅外肿瘤的活性相当。
